Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.

ABSTRACT:

Importance

The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described.

Objective

To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development.

Design, setting, and participants

This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with stage III/IV NSCLC, treated with anti-PD-(L)

SUBMITTER: Shankar B 

PROVIDER: S-EPMC7596677 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature